114,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients and close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of nanomedicine in detail to help understand the great promise of nanomedicine across all disease areas. It presents the topic of nanomedicine, although rich in content, to a wide audience by avoiding scientific jargon and by explaining all special terms and concepts from the ground up while introducing them.…mehr

Produktbeschreibung
By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients and close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of nanomedicine in detail to help understand the great promise of nanomedicine across all disease areas. It presents the topic of nanomedicine, although rich in content, to a wide audience by avoiding scientific jargon and by explaining all special terms and concepts from the ground up while introducing them.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Autorenporträt
Dr. Michael Hehenberger is founder of HM NanoMed LLC, Connecticut, USA. He retired after a long career with IBM at the end of 2013. He earned a Dipl. Ing. in physics from the Technical University of Vienna, Austria, and obtained his Ph.D. and Dr. Sc. degrees in quantum chemistry from Uppsala University, Sweden, in 1975-79. He also spent two years at the University of Florida, Gainesville, USA, as visiting associate professor. In 1985, he joined IBM in Stockholm, Sweden, to initiate academic partnerships in computational biology, structural engineering, computer networks, and supercomputing. Throughout his IBM career that took him to European Headquarters in Paris, California (Almaden Research, San Jose), and New York, he has led collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational chemistry and biology, information-based medicine, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.